FDA Guidance On Health Care Economic Data Is Coming In 2015
This article was originally published in The Pink Sheet Daily
Agency originally said it would issue a draft guidance on industry’s interactions with formulary committees in 2014, but CDER Director Woodcock says “extremely contentious” issues have slowed progress.
You may also be interested in...
Off-Label Preclearance Process Eyed As Potential Fix For FDA's Policy Dilemma
However, FDA lacks funding to promptly respond to off-label promotion submissions on broad scale; model outlined in settlement of Amarin's Vascepa case could bolster support for third-party vetting system.
Off-Label Questions Linger: How Much Data Needed To Be 'Truthful'?
FDA settlement with Amarin on Vascepa has done little to clarify what constitutes 'non-misleading' communications about an unapproved use.
Off-Label Promotion Settlement Includes Optional Preclearance Process
Amarin may submit up to two proposed communications annually to FDA about unapproved use of its triglyceride-lowering drug Vascepa, and the agency must respond with any concerns within 60 calendar days.